Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Absolutely awesome Tremors. Great job. It is also cool because you are in this same business.
Thanks again tremors. The more detail that you can provide us the better. Thanks in advance.
Great dd tremors.
Thanks. I think you are right that they had a part in that run up. Really interested to know what you find out.
Thanks buddy. My suspicion is that a new campaign will start this fall with the new catalysts. What do you think?
Another week is finished before take off. Trying to clear some more money for one last buy. Stay strong friends. When it goes, it's going to be good.
I don't have the time to do this right now, but the attached website lists a bunch of websites that will have all this information of recent hedge funed 13(d) and (g). Maybe someone will find it.
http://www.davemanuel.com/hedge-fund-filings.php
This is the response from the Cancer Vaccine and Gene Therapy:
Jack,
The titles of each presentation will be posted early next week, but the full abstracts will not be posted online.
Regards,
Justin
I guess we will at least know the title and probably who is presenting it. Interesting.
Last year ONCS presented their interim melanoma data at an "Advances in Immunotherapy" Regional Meeting at UCSF. Dr. Daud presented the data.
I went through the presentations at the regional sites and possibility is on December 5 where one of our Melanoma advisory board members, Dr. Sondak from Moffit, is presenting the following:
Adjuvant Immunotherapy for High-Risk Melanoma: Where Have We Been and Where Are We Going?
Vernon K. Sondak, MD – Moffitt Cancer Center
http://www.sitcancer.org/sitc-meetings/aci2014/fl/schedule
By the way, the topic of last year's presentation at the Cancer vaccines and Gene therapy was combination data with pd-1.
http://oncosec.com/oncosec-medical-announces-positive-preliminary-safety-data-in-combination-study/
Also, the Cancer Vaccines and Gene Therapy Meeting (10/6-10/7) is still accepting late-breaking abstracts. On the website, it states that ONCS is planning to present at this conference and is a sponsor of the event. I have written to the conference asking whether they are going to put the abstracts online. I'll let the board know when/if I get a response.
http://www.ngtcancervaccines.com/SubmitAbstract.html
Dr. Daud presented data for ONCS at last year's conference.
http://www.ngtcancervaccines.com/Agenda.html
I believe that the World Cutaneous Malignancies Congress is a real possibility for MCC. Our investigator, Dr. Bhatia, is already speaking on alternatives to chemotherapy for MCC. The abstract submission deadline is September 5, 2014 with the accepted abstracts put on the WCMC website. Not saying it will happen but a really good possibility. ONCS presented data there last year as well.
http://www.cutaneousmalignancies.com/conference/abstracts
Fair enough.
Furbush: how is the second article coming?
I'm in. Now That is a product that the FDA will approve with minimal. Whining is the worst. Just ask any parent, nothing worse. Whining is a huge unmet medical need!!!!
If you do recommend this, make sure that there are not significant SAE's. We need these guys and we don't need any distractions at the monthly meeting.
Lol!! Good to hear from you again wait.
And, the reason that I post these comparisons is to reassure the investors here that this kind of manipulation has happened many times before but the reversal is sweet. Good luck to you as well.
Really, not comparable!!! With all your reasoning it was bought down to .50!!!!! That is a bigger decrease than we have seen here by far. Just keeping it real.
It will happen soon enough and the IR department will be flooded with high fives instead of complaints. Keep your spirits up.
Guys, I've been saying this for weeks now but my thoughts are still the same:
You should be jumping for joy that these mm's have brought this down like this for the following reasons:
1. It had given you all incredible opportunities to buy at gift prices making your investment much more valuable.
2. When it runs, it will run much much harder and go much higher. A good comparison that jbeam77 brought to my attention is idra where these mms brought it down from $7.00 to .50!!! Three months later it was ) $6.00-7.00.
Just use your brains a buy if you think it's a good value. I just wish I had more available money to take advantage of this opportunity.
Thanks. I was just focusing on the ones that they actually are presenting at. Ex., world cutaneous cancer conference had several of our scientists/investigators, etc. but not mention of an oncs presentation. Speaking of that one, however, dr. Bahia (investigator for MCC), is presenting novel alternatives for chemo for MCC. That would be a great place to announce the MCC.
Well, oncs is sponsoring the gene therapy conference and they presented data there last year. That would be my best guess.
So, confirmed fall dates so far are:
1. 9/8-11--r and r
2. 10/6-7--cancer and gene therapy
ONCS presenting at Rodman and Renshaw HealthCare Conference: September 8-11.
http://www.meetmax.com//sched/event_23003/~public/conference_companies.html?event_id=23003
Great volume again. Love it.
Of course. I'm being slightly sarcastic. I just think what furbush did was awesome.
Furbush is now responsible for 26% now. Well done man. :)
Well, everything seems back to normal for the moment. Pps going up, no one cares about Punit's twitter usage and jj is running like mad. All good again. Enjoy the ride up my friends.
That is an awesome piece!!! Thanks Jeff.
The same clowns that drove this down will be the same ones driving it up past out wildest imaginations. Further, the same weak hands that allowed them to drive it down by selling on no bad news will be the same ones chasing when it flies. I have a big stake and will enjoy riding on their coattails.
I guess we might find out that Charlie furbush is our secret "highly respected" investors.
This was written by Punit in December of 2013. Very information.
2014 Is Poised to be a breakout year for Cancer Immunotherapy
In the December 2013 issue of Science, Cancer Immunotherapy was named as the Breakthrough of the Year. My initial reaction to this was a little shocking and wondering what finally swayed the sceptics to realize this? Internally, we have been calling it a breakthrough for sometime, what did we mean by calling it a breakthrough in the first place?
If is not clear, immunotherapy may very well be the end for Cancer even if the future remains a question mark. In the previous few ASCO meetings immune checkpoint blockers has brought forth encouragement for people suffering with Cancer and undoubtedly become the highest-profile area of drug development. It has been driven by remarkable data seen in early clinical studies of the anti-PD-1/PDL-1 agents that has marked out this drug class as the potential future cornerstone of therapy for many solid tumours. This is a radically different way of treating cancer – by targeting the immune system, not the tumour itself.
At the foundation of the immune response we need T cells that play a central role in cell-mediated immunity. T cells are immune cells that are ordinarily activated in response to cancer cells in order to seek and destroy them. T cells also have a regulator switch in the form of PD-1 on there surface to stop them from continuous destruction once the target cells are gone, this acts as a failsafe to stop them from destroying healthy tissue – hence, the origin of the term immune checkpoint. However, cancer continues to evolve and become intelligent and tumour cells have evolved by producing the ligand PD-L1 and PD-L2 on the surface. This naturally produced ligand binds PD-1 and trips the shutdown switch stopping the T Cells from doing there job. The objective of the checkpoint blockers is come between the receptor and the ligand, turning the switch back on and freeing the T cells to attack cancer. This is commonly referred to as removing the veil or cutting the “brakes,” which stops immune cells to see tumour cells as “self” and an immune response to continue.
What is cancer Immunotherapy?
Immunotherapeutic approaches leverage the patient’s immune system to eliminate or slow the growth and spread of cancerous cells. Older biologic agents such as interferon alpha2b and Proleukin (IL-2) were used with some success in the 1990’s but had limited impact given high toxicity and limited patient responsiveness in only select tumour types. New advances in tumour biology are enabling the development of newer potent T-cell mediated therapies that prevent the tumour from evading immune detection with manageable safety profile. Experimental T-cell immunotherapy comprises multiple modalities. These include checkpoint blockers (such as, anti-CTLA-4, anti-PD1/ PDL-1, CD137 etc.), therapeutic vaccines, oncolytic viruses, bispecific antibody-based approaches, small molecules and more recently cell-based therapies. A report published by Citi Research on Immunotherapy in May 2013 estimated the market for immunotherapeutic approaches in cancer treatment will likely exceed $35bn by 2023, driven by novel agents, combination therapy, longer treatment times and the emergence of predictive biomarkers.
Citi Research further went on to conclude that, “in 10 years, immunotherapy will likely form the backbone of 60% of all cancer management regimes in the developed world given likely paradigm shifting changes in OS improvements in responsive patients.”
Immunotherapy will likely form the backbone of c.60% of all cancer treatment in 10 years compared with <3% today
Who are the players dominating the immune checkpoint blockers space?
Bristol-Myers Squibb’s anti-PD-1 agent, nivolumab, has shown remarkable activity and duration of response in melanoma and several other indications this year, which has propelled it up the industry rankings to become the most valuable oncology project and its two close competitors, Merck & Co’s anti-PD-1 antibody MK-3475/ lambrolizumab and Roche’s anti-PDL-1 antibody, RG7446 (MPDL3280A), follow closely behind. Merck has significant basic science research experience backing its anti-PD-1. While Roche has no other late-stage checkpoint inhibitors, it has an immune-conjugate platform and leading monoclonal antibody design expertise, which facilitates the development of many anti-PDL-1 based combination therapies.
The anti-PD-1/PDL-1 agents appear to be on a path towards becoming a cornerstone of therapy for many, perhaps even most, solid tumours. Most of the studies to date have been of monotherapy. Yet the real potential of these drugs may lie in there use in combination, either with other immunotherapy agents, cancer vaccines or types of cancer drugs. Although it is still too early to tell whether they will be used in combination or sequence with existing therapies. 2014 should see key study readouts for the three anti-PD-1/PDL-1 agents that could inform this debate, as well as the start of new studies that look set to define the emerging competitive landscape.
http://punitdhillon.com/category/insight/
Btw, punit personal blog had some great stuff on it. It's actually a lot better designed than oncs' website.
Great Blog by Punit about Dr. Kohrt:
Dr. Kohrt Adds Some Clout
Today I am proud to announce the appointment of Dr. Holbrook Kohrt to OncoSec’s Scientific Advisory Board. Holbrook is brilliant physician and researcher with extensive knowledge in tumor immunology and clinical trial design. He has an M.D. and 2 Ph.D.’s from Stanford University, where he currently researches novel therapeutic strategies to enhance anti-tumor immunity. Specifically, Dr. Kohrt is interested in augmenting antibody therapy for treating cancer by identifying and developing immunomodulatory antibodies targeting immune effector cells subsets – such as natural killer cells – which enhance the anti-tumor activity of tumor-targeting antibodies.
Today’s cancer immunotherapy is driven by monoclonal antibodies; it primarily targets the quantity and quality of immune effector cells
Driving a successful tumor-killing immune response is analogous to driving a car, where one would seek to “fill the gas tank” with tumor infiltrating lymphocytes (TILs), take a “foot off the brake” with the inhibition of immune checkpoints and put a “foot on the gas” via co-stimulatory activation. Older immunotherapy treatment options like interleukin-2 (Proleukin) and interferon-alpha (PEG- Intron/Intron A) focused on non-selective T cell priming, via stimulating expansion and maturation of T cells. Current targets (PD1/L1, CTLA4) focus on inhibiting checkpoint activation with targeted monoclonal antibodies. These monoclonal antibodies (mAbs) bind to cell ligands and receptors, interfere with checkpoint activation and suppress inhibitory feedback loops.
ImmunoPulse may reverse the immunosuppressive tumor microenvironment directly with local intralesional therapy, using potent pro-inflammatory molecules like IL-12. Pre-clinical data, though preliminary, paint the picture that intratumoral electroporation of pIL-12 is driving a conversion from a low TIL to a high TIL phenotype and supports our rationale for a combination approach with an anti-PD-1 (or, anti-PD-L1) mAb.
Rapidly emerging data suggests that the promise of immunotherapy can and likely will be expanded to a much broader range of tumors with the introduction of new checkpoint and co-stimulatory targets, as well as a wide range of immunotherapy combinations. Restoring appropriate function of the cancer-immunity cycle holds the promise of either holding cancer in check or “curing” a patient of disease.
Through his work at Stanford, Holbrook has established himself as an academic leader in intratumoral immuno-oncology. We are thrilled to have his guidance and expertise during this transformational moment, where technologies like those being advanced by the OncoSec team have the potential to fundamentally impact the cancer treatment landscape. The ultimate goal of all cancer treatment is to “lift the curve” of survival with complete responses (CRs) where treatment can be successfully discontinued, responses are ongoing and the patient is essentially cured. Thanks to the work of researchers like Dr. Kohrt, emerging immunotherapies may make this goal a reality for many patients in the future.
http://punitdhillon.com/2014/08/06/dr-kohrt-adds-some-clout/
Love the volume.
Here is some more info on Dr. Kohrt:
http://ssps.stanford.edu/Scholar/IndividualScholarsPages/HolbrookKohrt.html
http://stanfordhealthcare.org/doctors/k/holbrook-kohrt.html
You have been. 13.30% so far. :)
I don't care what anyone says, I attribute today's gain solely to furbush.
Well, looks like we found our bottom. 750k shares in the first 18 min. Nice.